文献速递银屑病与炎症性皮肤病

HB0017(靶向IL-17A人源化单抗)在健康受试者及中重度斑块状银屑病患者中的安全性、耐受性、药代动力学与疗效

Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis.
PubMed 文献 · Br J Dermatol · 2023-01-01

该研究包含Ia期和Ib期随机双盲安慰剂对照剂量递增试验,评估HB0017在健康受试者和中重度斑块状银屑病患者中的安全性、耐受性、药代动力学及疗效。HB0017呈现剂量比例线性药代动力学特征且耐受性良好,300 mg组患者PASI 75、PASI 90和sPGA 0/1应答率均为100%,安慰剂组无临床应答。

要点

  • HB0017在健康受试者和中重度斑块状银屑病患者中显示可接受的安全性和耐受性。
  • HB0017呈现剂量比例线性药代动力学特征。
  • 300 mg组患者PASI 75、PASI 90和sPGA 0/1应答率均为100%,安慰剂组无临床应答。

核心结论

  • HB0017在健康受试者和中重度斑块状银屑病患者中显示可接受的安全性和耐受性。
  • HB0017展现出令人鼓舞的疗效信号且半衰期较长,有潜力加入现有靶向IL-17A的生物制剂系列。

研究设计与样本

  • Ia期研究(NCT04505033)为随机双盲安慰剂对照剂量递增研究,纳入健康受试者,每个队列10名志愿者按4:1随机接受单剂HB0017(50 mg、150 mg、300 mg或450 mg)或匹配安慰剂。
  • Ib期研究(NCT05442788)为随机双盲安慰剂对照剂量递增研究,纳入中重度斑块状银屑病患者,每个队列10名患者按4:1随机接受多剂HB0017(150 mg、300 mg或450 mg)或匹配安慰剂。

主要发现

  • HB0017呈现剂量比例线性药代动力学特征,在所评估剂量范围内耐受。
  • Ia期研究中HB0017组与安慰剂组治疗中出现的不良事件发生率分别为69% vs. 87%。
  • Ib期研究中HB0017组与安慰剂组治疗中出现的不良事件发生率分别为96% vs. 100%。
  • HB0017在中重度斑块状银屑病患者中显示出有临床意义的疗效。
  • HB0017 300 mg组PASI 75、PASI 90和sPGA 0/1应答率均为100%,PASI评分最大改善(较基线降低100%或接近100%)见于第12周,疗效持续时间明显可达第20周;Ib期研究中安慰剂组无任何参与者出现临床应答。

关键数值与推荐

  • Ia期研究:每个队列10名健康志愿者按4:1随机接受单剂HB0017(50 mg、150 mg、300 mg或450 mg)或匹配安慰剂。
  • Ib期研究:每个队列10名中重度斑块状银屑病患者按4:1随机接受多剂HB0017(150 mg、300 mg或450 mg)或匹配安慰剂。
  • HB0017 300 mg组PASI 75、PASI 90和sPGA 0/1应答率均为100%。
  • HB0017 300 mg组PASI评分最大改善(较基线降低100%或接近100%)见于第12周,疗效持续时间明显可达第20周。

临床怎么用

  • HB0017在中重度斑块状银屑病患者中显示出有临床意义的疗效信号,且半衰期较长,有潜力加入现有靶向IL-17A的生物制剂系列。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several interleukin (IL)-17 inhibitors have been approved for the treatment of moderate-to-severe plaque psoriasis (PsO). There is still scope for the development of affordable treatments for PsO. OBJECTIVES: To assess, in a phase Ia study, the safety, tolerability and pharmacokinetics (PK) of HB0017, a humanized monoclonal antibody that targets IL-17A, in healthy participants and patients with moderate-to-severe plaque PsO; and, in a phase Ib study, to assess the efficacy of HB0017 in patients with moderate-to-severe plaque PsO. METHODS: The phase Ia study (NCT04505033) was a randomized double-blind placebo-controlled dose-escalation study in healthy participants. Each cohort of 10 volunteers was randomly assigned to receive either a single dose of HB0017 (50 mg, 150 mg, 300 mg or 450 mg) or the matching placebo at a ratio of 4 : 1. The phase Ib study (NCT05442788) was a randomized double-blind placebo-controlled dose-escalation study in enrolled patients with moderate-to-severe plaque PsO. Each cohort of 10 patients was randomly assigned to receive either multiple doses of HB0017 (150 mg, 300 mg or 450 mg) or the matching placebo at a ratio of 4 : 1. RESULTS: HB0017 demonstrated dose-proportional linear PK and was tolerated across the dose range assessed. In the phase Ia and Ib studies, participants in both the HB0017 and placebo groups experienced treatment-emergent adverse events (69% vs. 87%, 96% vs. 100%, respectively). HB0017 demonstrated clinically meaningful effects in patients with moderate-to-severe plaque PsO. PASI 75 [≥ 75% improvement in Psoriasis Area and Severity Index (PASI)], PASI 90 (≥ 90% improvement in PASI) and static Physician Global Assessment (sPGA) 0/1 (i.e. 'clear' or 'almost clear') responses were 100% for the HB0017 300-mg group, with maximal improvements (100% or near 100% reductions from baseline) in PASI score observed at week 12, while the duration of effect was evident up to week 20. There was no clinical response in any participant in the placebo group in the phase Ib study. CONCLUSIONS: Overall, HB0017 showed acceptable safety and tolerability in both healthy participants and patients with moderate-to-severe plaque PsO. An encouraging signal of efficacy with a longer half-life provides HB0017 with the potential to be added to the currently available range of biologics targeting IL-17A.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Jiang C, Du Y, Liu X, et al. Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2023. PMID: 37669307. doi:10.1093/bjd/ljad315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。